Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome
NCT07531940Phase 1Not yet recruiting
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Oct 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of memantine in Down syndrome and Alzheimer's disease (AD), sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Incidence of Adverse Events at 36 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
memantine
03
Conditions
Down syndromeAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07531940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531940.